Stockholm, Sweden

Christina Johansson


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christina Johansson: Innovator in Pharmaceutical Composition

Introduction

Christina Johansson is a notable inventor based in Stockholm, Sweden. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug delivery systems. Her work focuses on improving the efficacy of treatments for various lung diseases.

Latest Patents

Christina Johansson holds a patent for a delayed release composition for peroral administration. This pharmaceutical composition includes N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof. The composition is designed to be protected by a coating comprising an enteric substance. Preferred dosage forms include capsules that present C21 or its salt in the form of a dry powder mixture or a suspension of particles in an insoluble solvent. This innovative approach is particularly useful in treating lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and respiratory virus-induced tissue damage.

Career Highlights

Christina Johansson has established herself as a key figure in the pharmaceutical industry. Her work at Vicore Pharma AB has been instrumental in advancing drug formulations that enhance patient outcomes. With her expertise, she continues to push the boundaries of pharmaceutical science.

Collaborations

Christina collaborates with Ola Camber, contributing to the development of groundbreaking pharmaceutical solutions. Their partnership exemplifies the importance of teamwork in driving innovation in the industry.

Conclusion

Christina Johansson's contributions to pharmaceutical compositions highlight her role as an innovator in the field. Her patent for a delayed release composition demonstrates her commitment to improving treatments for lung diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…